Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1175982.RAFBvz0NHgeDT2qXeq8bOGNBF50YW7YcGzFKJcQhHIM0g130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1175982.RAFBvz0NHgeDT2qXeq8bOGNBF50YW7YcGzFKJcQhHIM0g130_assertion type Assertion NP1175982.RAFBvz0NHgeDT2qXeq8bOGNBF50YW7YcGzFKJcQhHIM0g130_head.
- NP1175982.RAFBvz0NHgeDT2qXeq8bOGNBF50YW7YcGzFKJcQhHIM0g130_assertion wasGeneratedBy ECO_0000203 NP1175982.RAFBvz0NHgeDT2qXeq8bOGNBF50YW7YcGzFKJcQhHIM0g130_provenance.
- NP1175982.RAFBvz0NHgeDT2qXeq8bOGNBF50YW7YcGzFKJcQhHIM0g130_assertion wasDerivedFrom befree-2016 NP1175982.RAFBvz0NHgeDT2qXeq8bOGNBF50YW7YcGzFKJcQhHIM0g130_provenance.
- NP1175982.RAFBvz0NHgeDT2qXeq8bOGNBF50YW7YcGzFKJcQhHIM0g130_assertion SIO_000772 24757092 NP1175982.RAFBvz0NHgeDT2qXeq8bOGNBF50YW7YcGzFKJcQhHIM0g130_provenance.
- NP1175982.RAFBvz0NHgeDT2qXeq8bOGNBF50YW7YcGzFKJcQhHIM0g130_assertion evidence source_evidence_literature NP1175982.RAFBvz0NHgeDT2qXeq8bOGNBF50YW7YcGzFKJcQhHIM0g130_provenance.
- NP1175982.RAFBvz0NHgeDT2qXeq8bOGNBF50YW7YcGzFKJcQhHIM0g130_assertion description "[These results indicate that reduction of TNFR2+ T cells in AML postremission phase may result from combined azacitidine/lenalidomide therapy and may contribute to an improved clinical outcome.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1175982.RAFBvz0NHgeDT2qXeq8bOGNBF50YW7YcGzFKJcQhHIM0g130_provenance.